UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-40789 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2967193 (State or other jurisdiction of (IRS Employer incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40789 FIRST LIGHT ACQUISITION GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 86-2967193 (State or other jurisdict ...

首次公开募股 - 公司于2021年9月14日完成首次公开募股，发行了23,000,000单位，募集约2.3亿美元[108] 财务状况 - 截至2023年3月31日，公司净亏损约220万美元，主要由运营成本、前期购买单位责任公允价值变动损失、未来利息责任公允价值变动损失和所得税准备等构成[112] 公司活动 - 公司自成立以来至2023年3月31日，活动主要集中在公司的形成、首次公开募股以及寻找业务组合候选公司[111] 业务合并 - 公司对于与Calidi的业务合并的前瞻性购买协议不承担购买义务，并决定不购买这些股票[127] 会计处理 - 公司根据美国通用会计准则对14,897,155份权证进行会计处理，将其作为权益类或负债类工具，并根据ASC 480和ASC 815的相关指导进行评估[129] - 公司根据ASC Topic 815对5,000,000份前瞻性购买单位进行会计处理，将其作为负债类工具按公允价值计量，并在后续报告日期记录公允价值变动[130]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40789 First Light Acquisition Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 86-2967193 (State or other ...